<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-146792</identifier>
<setSpec>1134-5934</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Controversies regarding plasmatic levels of clozapine: review and a case report</dc:title>
<dc:description xml:lang="en">Clozapine should be considered as first-line treatment in individuals with a diagnosed treatment-resistant schizophrenia. Despite alternative treatments and augmentation strategies available, there is no consistent evidence that none of these options produce substantive clinical gains when clozapine-treated patients demonstrate a suboptimal clinical response. It is therefore important that we optimize clozapine treatment in these patients. One of the clinical tools to assist in this has been therapeutic drug monitoring of plasmatic levels, because it provides drug concentrations associated with highest probability of response and a low risk of side effects. A number of studies have addressed the therapeutic range of clozapine's plasmatic level, and reviews of this topic have generally agreed that the lower threshold is around 350 ng/ml. In contrast, the issue of an upper threshold is more complex and there is no agreed for an upper limit associated with clozapine toxicity. We report a case of a patient with the diagnosis of treatment-resistant schizophrenia treated with clozapine in which we think that therapeutic drug monitoring of clozapine plasmatic could influence treatment decisions (AU)</dc:description>
<dc:creator>Oller-Canet, Silvia</dc:creator>
<dc:creator>Samsó-Buxareu, Berta</dc:creator>
<dc:creator>Alba-Palé, Leila</dc:creator>
<dc:creator>Pérez, Víctor</dc:creator>
<dc:creator>León-Caballero, Jordi</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La clozapina es el fármaco de primera elección en el manejo de la esquizofrenia resistente al tratamiento, y no existe ninguna alternativa terapéutica que haya demostrado mayor eficacia en estos pacientes. Por ello es importante optimizar el tratamiento con clozapina en la esquizofrenia resistente. Una de las herramientas clínicas de las que se dispone es la monitorización de los niveles plasmáticos del fármaco, ya que permite asegurar que el paciente está dentro del rango terapéutico y disminuye el riesgo de efectos adversos. La evidencia disponible concluye en establecer un límite inferior alrededor de los 350 ng/ml. Sin embargo, la cuestión del límite superior del intervalo es más compleja y no existe un acuerdo sobre la concentración sanguínea de clozapina que se asocia a toxicidad. Presentamos un caso clínico de un paciente con esquizofrenia resistente en tratamiento con clozapina, en el cual la monitorización de niveles plasmáticos pudo influir en las decisiones terapéuticas (AU)</dc:description>
<dc:source>Psiquiatr. biol. (Ed. impr);22(3): 80-82, sept.-dic. 2015. tab</dc:source>
<dc:identifier>ibc-146792</dc:identifier>
<dc:title xml:lang="es">Controversias sobre los niveles plasmáticos de clozapina: revisión a propósito de un caso</dc:title>
<dc:subject>^d331</dc:subject>
<dc:subject>^d3051^s22062</dc:subject>
<dc:subject>^d3051^s22073</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d12944^s22057</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d22164</dc:subject>
<dc:type>article</dc:type>
<dc:date>201512</dc:date>
</metadata>
</record>
</ibecs-document>
